I'm LongbridgeAI, I can summarize articles.WINTON GROUP Ltd invested $1.41 million in Merus N.V., purchasing 26,723 shares. Merus's stock opened at $96.36, with a market cap of $7.31 billion. Analysts have mixed ratings, with a consensus "Hold" and a target price of $93.56. Merus develops antibody therapeutics, with key candidates in clinical trials.
WINTON GROUP Ltd purchased a new stake in Merus N.V. (NASDAQ:MRUS - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 26,723 shares of the biotechnology company's stock, valued at approximately $1,406,000.
Other institutional investors also recently modified their holdings of the company. US Bancorp DE lifted its position in shares of Merus by 324.1% during the 1st quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company's stock worth $124,000 after buying an additional 2,243 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Merus by 30.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,800 shares of the biotechnology company's stock valued at $244,000 after buying an additional 1,340 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Merus by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,101 shares of the biotechnology company's stock valued at $257,000 after acquiring an additional 511 shares during the last quarter. Invesco Ltd. lifted its holdings in Merus by 5.3% during the 1st quarter. Invesco Ltd. now owns 828,217 shares of the biotechnology company's stock worth $34,860,000 after buying an additional 41,852 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Merus by 955.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 1,624 shares during the last quarter. Institutional investors and hedge funds own 96.14% of the company's stock.
Merus Price Performance
Shares of MRUS opened at $96.36 on Wednesday. Merus N.V. has a 1 year low of $33.19 and a 1 year high of $96.42. The stock's fifty day moving average price is $95.26 and its two-hundred day moving average price is $73.73. The firm has a market cap of $7.31 billion, a PE ratio of -18.18 and a beta of 1.06.
Insider Activity at Merus
In related news, VP Harry Shuman sold 8,300 shares of the firm's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $95.92, for a total value of $796,136.00. Following the completion of the transaction, the vice president directly owned 11,002 shares of the company's stock, valued at approximately $1,055,311.84. This trade represents a 43.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.70% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. Lifesci Capital reissued a "market perform" rating and issued a $97.00 price objective on shares of Merus in a research report on Tuesday, September 30th. Guggenheim reiterated a "neutral" rating and issued a $97.00 target price (down previously from $109.00) on shares of Merus in a research note on Tuesday, September 30th. UBS Group lowered Merus from a "buy" rating to a "neutral" rating and lifted their price target for the stock from $72.00 to $97.00 in a report on Tuesday, September 30th. Needham & Company LLC cut Merus from a "buy" rating to a "hold" rating and set a $96.00 price objective on the stock. in a research report on Monday, September 29th. Finally, Leerink Partners restated a "market perform" rating and issued a $97.00 price objective (up previously from $95.00) on shares of Merus in a research note on Monday, October 6th. Three research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Merus presently has a consensus rating of "Hold" and a consensus target price of $93.56.
Read Our Latest Stock Analysis on MRUS
About Merus
(Free Report)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Read More
- Five stocks we like better than Merus
- How to Profit From Growth Investing
- Ollie’s Bargain Outlet Hits Rock-Bottom in Q4: Buy the Dip?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Insiders Are Selling These 3 Stocks—Here’s Why
- How to Read Stock Charts for Beginners
- Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Merus Right Now?
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here